AMICUS THERAPEUTICS, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
State of Incorporation
DE
Business Address
47 HULFISH STREET, PRINCETON, NJ, 08542
Mailing Address
47 HULFISH STREET, PRINCETON, NJ, 08542
Phone
(609) 662-2000
Fiscal Year End
1231
EIN
200422823
Financial Overview
FY2025
$949.87M
Total Assets
$-0.09
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 8-K Current report of material events | March 3, 2026 | View on SEC |
| 8-K Current report of material events | February 20, 2026 | View on SEC |
| 10-K Annual financial report | February 20, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 10, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 9, 2026 | View on SEC |
| 8-K Current report of material events | January 26, 2026 | View on SEC |
| 4 Insider stock transaction report | January 22, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
Annual Reports
10-K
February 20, 2026
- Strong 2025 performance with 22% revenue growth, driven by Galafold and Pombiliti/Opfolda.
- Significant pipeline investment, particularly in gene therapy for rare neurological disorders, with promising Phase 2 data.
Insider Trading
STRONG SELL
2 insiders
5 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.